Synthesis and SAR Studies of Fused Oxadiazines as γ‑Secretase Modulators for Treatment of Alzheimer's Disease
journal contributionposted on 20.02.2016, 06:50 authored by Xianhai Huang, Wei Zhou, Xiaoxiang Liu, Hongmei Li, George Sun, Mihirbaran Mandal, Monica Vicarel, Xiaohong Zhu, Chad Bennett, Troy McCraken, Dmitri Pissarnitski, Zhiqiang Zhao, David Cole, Gioconda Gallo, Zhaoning Zhu, Anandan Palani, Robert Aslanian, John Clader, Michael Czarniecki, William Greenlee, Duane Burnett, Mary Cohen-Williams, Lynn Hyde, Lixin Song, Lili Zhang, Inhou Chu, Alexei Buevich
Fused oxadiazines (3) were discovered as selective and orally bioavailable γ-secretase modulators (GSMs) based on the structural framework of oxadiazoline GSMs. Although structurally related, initial modifications showed that structure–activity relationships (SARs) did not translate from the oxadiazoline to the oxadiazine series. Subsequent SAR studies on modifications at the C3 and C4 positions of the fused oxadiazine core helped to identify GSMs such as compounds 8r and 8s that were highly efficacious in vitro and in vivo in a number of animal models with highly desirable physical and pharmacological properties. Further improvements of in vitro activity and selectivity were achieved by the preparation of fused morpholine oxadiazines. The shift in specificity of APP cleavage rather than a reduction in overall γ-secretase activity and the lack of changes in substrate accumulation and Notch processing as observed in the animal studies of compound 8s confirm that the oxadiazine series of compounds are potent GSMs.